Does berberine lower triglycerides?

It suppresses hepatic lipogenesis through AMPK and SREBP-1c, and lipid reductions are commonly reported in metabolic trials. No studies are currently linked to this pairing.

How much should I take?

500 mg three times daily with meals is conventional, titrated up from a single daily dose over one to two weeks.

Can I take berberine with a statin?

Not without medical review. Berberine inhibits CYP3A4, which can raise levels of several statins and increase muscle toxicity risk.

When should I recheck my lipids?

After about 12 weeks, using a properly fasted sample since triglycerides are highly meal-sensitive.

Does it reduce heart attack risk?

There is no evidence of that. Trials show biomarker changes only, with no cardiovascular outcome data.

Outcome

Moderate Evidence

Berberine for Triglyceride Reduction

Berberine produces genuine triglyceride and glycaemic improvements in metabolic syndrome.

Overview

Berberine is unusual among supplements in having a lipid effect as well as a glucose effect. Alongside its metabolic reputation, it consistently appears in the literature as a triglyceride- and LDL-lowering agent, acting through a mechanism distinct from statins.

Raised triglycerides usually travel with insulin resistance, central adiposity, alcohol intake and high refined carbohydrate consumption, so anything that improves glucose handling tends to move triglycerides too. Berberine plausibly acts through both routes at once. The practical caveat is proportion. Dietary change - cutting alcohol, sugar and refined starch - and weight loss usually produce larger triglyceride reductions than any supplement, and severe hypertriglyceridaemia is a medical problem requiring prescription treatment.

No studies are currently linked to this pairing

This page reflects established pharmacology and conventional dosing rather than trial data attached to this outcome in our library.

How It Works

Berberine activates AMP-activated protein kinase in the liver, which suppresses the lipogenic transcription factor SREBP-1c and reduces de novo synthesis of fatty acids and triglycerides. Less hepatic production means less VLDL exported into circulation.

Its LDL effect operates by a different route: berberine stabilises LDL receptor mRNA, increasing receptor density on hepatocytes and clearance of circulating LDL. This is mechanistically separate from statins, which inhibit cholesterol synthesis, which is why the two have been studied in combination. AMPK activation also promotes fatty acid oxidation, and improved insulin sensitivity reduces the substrate flux to the liver that drives triglyceride production in the first place.

Dosing & Protocol

The lipid literature uses the same divided dosing as the metabolic literature, taken with meals and titrated upward.

Context	Dose	Form	Timing
Conventional lipid dose	500 mg three times daily	Berberine HCl	With or just before meals
Starting dose	500 mg once daily	Berberine HCl	With the largest meal, for 1 week
Enhanced bioavailability form	200-500 mg daily	Dihydroberberine	With meals
Assessment point	Recheck lipids at 12 weeks	Fasting lipid panel	Fast 10-12 hours before testing

Fast properly before the blood test

Triglycerides are the most meal-sensitive lipid measure. A non-fasting sample can misrepresent your result by a wide margin in either direction.

Evidence

There are currently no studies linked to this pairing in our library, so no study list is shown.

The general berberine literature includes numerous 12 to 24 week trials in type 2 diabetes, metabolic syndrome and dyslipidaemia reporting reductions in triglycerides, total cholesterol and LDL alongside glucose improvements, with several meta-analyses pooling them. The recurring limitations are small sample sizes, concentration in Chinese populations, variable methodological quality and short duration. Crucially, no trials demonstrate reduced cardiovascular events - the outcome that matters - so the evidence remains at the level of biomarker change.

Biomarkers are not events

Lowering a number on a lipid panel is not the same as preventing a heart attack. Only statins and a few other drug classes have outcome trials behind them.

Safety

Gastrointestinal effects are the most common problem: cramping, diarrhoea, constipation and nausea, particularly when starting at the full dose.

Never in pregnancy or in newborns

Berberine crosses the placenta and displaces bilirubin from albumin, risking kernicterus. It is contraindicated in pregnancy, breastfeeding and infants.

Berberine inhibits CYP3A4, CYP2D6 and P-glycoprotein, which matters enormously here because most statins are CYP3A4 substrates - combining them can raise statin levels and myopathy risk. Triglycerides above 10 mmol/L carry a risk of acute pancreatitis and require urgent medical treatment, not supplementation.

Interactions & Conflicts

The lipid context makes the statin interaction the headline concern.

Interacts with	Severity	Mechanism	Action
Statins metabolised by CYP3A4 (simvastatin, atorvastatin)	high	Enzyme inhibition raises statin levels and myopathy risk	Do not combine without prescriber and pharmacist review
Anticoagulants including warfarin	high	Altered metabolism and possible antiplatelet effect	Avoid unless supervised with INR monitoring
Insulin and sulfonylureas	high	Additive glucose lowering	Monitor blood glucose closely
Ciclosporin and other narrow-margin CYP3A4 drugs	high	Substantially raised drug levels	Avoid

References

No studies are currently linked to this pairing, so no reference list is available. This section will populate as evidence is added to the library.

Frequently Asked Questions

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.